Organon & Co.
OGN
Classifica tra le azioni
#4361
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Prezzo delle azioni
$13.75
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$3.61B
Variazione (1 giorno)
-0.11%
Variazione (1 anno)
48.76%
Paese
US
Scambia Organon & Co. (OGN)
Categoria
Healthcare
Utile per Organon & Co. (OGN)
Utile nel Jun 2026 TTM: $491.00M
Secondo gli ultimi rapporti finanziari di Organon & Co., gli utili attuali della società sono $491.00M. Nel 2024, la società ha registrato un utile di $807.00M, un aumento rispetto a agli utili del 2023, che erano di $673.00M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Organon & Co. dal 2017 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $491.00M | 15.53% |
| 2025 | $425.00M | -47.34% |
| 2024 | $807.00M | 19.91% |
| 2023 | $673.00M | -40.02% |
| 2022 | $1.12B | -26.62% |
| 2021 | $1.53B | -44.44% |
| 2020 | $2.75B | -25.54% |
| 2019 | $3.70B | 35.43% |
| 2018 | $2.73B | -11.94% |
| 2017 | $3.10B | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $33.60B | 6,742.28% |
US
|
|
| $17.74B | 3,512.42% |
US
|
|
| $8.70B | 1,671.69% |
US
|
|
| $5.95B | 1,111.41% |
US
|
|
| $21.39B | 4,256.07% |
CH
|
